adults 70% of whom count as overweight or obese fully 12% are estimated to have used GLP-1s, and many lose 10% or more of their body weight when they do
In summary, there are evidence, that treatment with GLP-1RAs may prove useful in the treatment of depressive disorders, however, the number of reliable clinical reports concerning this matter remains very low at this point
Insulin resistance plays an important role in the pathophysiology of comorbid T2DM and depression and can be a trigger for dysregulation of insulin- and GLP-1-mediated signaling (both central and peripheral), neuroendocrine disorders (hypothalamicpituitaryadrenal system dysfunction and monoaminergic neurotransmission disorders), chronic low-intensity inflammation, oxidative stress, and disorders of the microbiota-gut-brain system, reducing the level of neurotrophic factors in the brain and changing synaptic plasticity
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes
Pradhan, R
Detka J, Kurek A, Kucharczyk M, Gombik K, Basta-Kaim A, Kubera M, et al
